SOMG-833

CAS No. 1268264-10-3

SOMG-833( SOMG 833 | SOMG833 )

Catalog No. M11122 CAS No. 1268264-10-3

A potent, selective, ATP-competitive c-MET inhibitor with IC50 of 0.93 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 1233 Get Quote
50MG 2502 Get Quote
100MG 3330 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    SOMG-833
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent, selective, ATP-competitive c-MET inhibitor with IC50 of 0.93 nM.
  • Description
    A potent, selective, ATP-competitive c-MET inhibitor with IC50 of 0.93 nM; displays >10,000-fold selectivity over panel of 20 kinases, including c-MET family member RON and highly homologous kinase AXL; significantly inhibits c-MET phosphorylation and the proliferation of c-MET-dependent EBC-1, MKN-45, SNU-5, and BaF3/TPR-MET cell lines with IC50 of 0.160-0.457 uM, through G1/S cell cycle arrest; demonstrates remarkable antitumor efficacy in vivo.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    SOMG 833 | SOMG833
  • Pathway
    Angiogenesis
  • Target
    c-Met/HGFR
  • Recptor
    c-Met/HGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1268264-10-3
  • Formula Weight
    445.446
  • Molecular Formula
    C22H22F3N5O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CN1CCN(CC1)C2=CC3=C(C=C(C=C3NCC4=CC(=CC=C4)[N+](=O)[O-])C(F)(F)F)N=C2
  • Chemical Name
    3-(4-methylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7-(trifluoromethyl) quinoline

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Zhang HT, et al. J Pharmacol Exp Ther. 2014 Jul;350(1):36-45.
molnova catalog
related products
  • JNJ-38877618

    JNJ-38877618 (OMO-1) is a novel potent, highly selective, orally bioavailable c-Met tyrosine kinase inhibitor.

  • Tepotinib hydrochlor...

    Tepotinib hydrochloride(1 : x) is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14 skipping mutations.

  • Cabozantinib hydroch...

    Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2 c-Met Kit Axl and Flt4 (IC50s: 0.035 1.3 4.6 7 and 6 nM).